Juan Fortea
Director of the Memory Unit of the Neurology Service of the Hospital de la Santa Creu i Sant Pau and director of the Alzheimer's Unit at the Fundació Catalana Sindrome de Down
I am extremely pleased with the recent approval of lecanemab by the EMA after reconsidering its decision in the appeal process. This breakthrough represents a milestone for Alzheimer's patients and marks a paradigm shift in their treatment.
Although use will be restricted to a minority in the early stages, it will drive the development of essential diagnostic and therapeutic capabilities, as was the case with stroke units, benefiting all patients, both those who receive the drug and those who do not.
This is excellent news, correcting a worrying decision and bringing Europe back to the forefront of Alzheimer's research and care.